SCHEMBL21990455

SCHEMBL21990455

CC(C)N(C)c1cc2c(c(CO)n1)CNC2=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 12/20 0.36
LCP2 Q13094 4/20 0.33
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
PRKD2 Q9BZL6 2/20 0.32
PLK4 O00444 1/20 0.32
CHEK1 O14757 1/20 0.32
DAPK3 O43293 1/20 0.32
ROCK2 O75116 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
CHEK2 O96017 1/20 0.32
PRKCG P05129 1/20 0.32
INSR P06213 1/20 0.32
LCK P06239 1/20 0.32
LYN P07948 1/20 0.32
RET P07949 1/20 0.32
PIM1 P11309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30227903 1.00 MAP4K1 (0.36) MAP4K1LCP2PIK3CDPIK3CAPIK3CB
SCHEMBL21990591 0.87 GRM2 (0.33) MAP4K1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21990672 0.85 MAP4K1 (0.46) MAP4K1LCP2PRKD2RPS6KA2
SCHEMBL30227802 0.85 MAP4K1 (0.46) MAP4K1LCP2PRKD2RPS6KA2
SCHEMBL21964196 0.84 MAP4K1 (0.33) MAP4K1LCP2
SCHEMBL21964197 0.84 MAP4K1 (0.35) MAP4K1LCP2PIK3CDPIK3CAPIK3CB
SCHEMBL21990619 0.82 PIK3CD (0.33) MAP4K1LCP2PIK3CDPIK3CAPIK3CB
SCHEMBL30227951 0.82 PIK3CD (0.33) MAP4K1LCP2PIK3CDPIK3CAPIK3CB
SCHEMBL25100230 0.81 MAP4K1 (0.38) MAP4K1LCP2PRKD2RPS6KA2
SCHEMBL30232898 0.81 MAP4K1 (0.38) MAP4K1LCP2PRKD2RPS6KA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2024-06-20 US disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-11684616-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2023-06-27 US disclosed
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2022-12-22 US disclosed
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2022-12-22 US disclosed
WO-2021220185-A1 AZALACTAM COMPOUNDS AS HPK1 INHIBITORS PFIZER INC. (US) 2021-11-04 WO disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
WO-2020100027-A1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401424-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 MAP4K1 108/4885LCP2 4392/4885PIK3CD 818/4885
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 MAP4K1 96/4885LCP2 4427/4885PIK3CD 892/4885
US-11142525-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 MAP4K1 96/4885LCP2 4427/4885PIK3CD 892/4885
US-11684616-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 MAP4K1 108/4885LCP2 4392/4885PIK3CD 818/4885
US-20240197703-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 MAP4K1 108/4885LCP2 4392/4885PIK3CD 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.